Allopartis Biotechnologies Inc.

Allopartis Biotechnologies Inc. focuses on developing advanced biologic therapies aimed at addressing complex health conditions through innovative biotechnology solutions. Allopartis Biotechnologies Inc. specializes in innovative biotechnology solutions and was founded in San Francisco, US.

The company received funding via a Seed round amounting to USD 0. 75 mn on October 10, 2013, with investors including California Clean Energy Fund and XSeed. In October 2013, Allopartis was acquired by Novozymes A/S, marking a significant transition in its operational strategy. Allopartis specializes in innovative solutions within the biotechnology sector, focusing on the development and distribution of advanced biologic therapies.

Their core product offerings include a range of therapeutic agents designed to address complex health conditions through targeted biological mechanisms. The company’s products aim to enhance patient outcomes by improving the efficacy of treatments while minimizing side effects, thereby catering to healthcare providers and patients alike. End users primarily include hospitals, clinics, and healthcare professionals who administer these therapies, targeting markets across North America, Europe, and parts of Asia. Allopartis has positioned itself to address unmet medical needs in these regions, leveraging cutting-edge research to deliver high-quality and impactful therapies.

Allopartis generates revenue through a structured model that encompasses partnerships with healthcare providers and distributors. The company engages in direct sales of its flagship biologic therapies, which are typically offered through both B2B transactions with hospitals and clinics, and potentially via direct-to-consumer channels in select markets. Revenue is structured around product sales, with potential for recurring income through subscription models for ongoing treatment regimens. In this scenario, a healthcare provider may establish a partnership with Allopartis to supply its therapies, thus committing to regular orders to ensure consistent patient access to these important treatments.

Pricing strategies for these products are determined based on market dynamics and competitive positioning within the biotechnology landscape. Allopartis Biotechnologies Inc. plans to expand its product line with new biologic therapies designed to meet specific medical needs, with a launch timeline yet to be announced. The company is also looking to penetrate additional markets in Europe and Asia by 2025.

The recent funding of USD 0. 75 mn will be utilized to support product development and market expansion efforts, particularly targeting regions where the demand for advanced biologic therapies is rapidly increasing.